Search results for "Oestrogen receptor"

showing 6 items of 6 documents

Genome-wide DNA methylation differences according to oestrogen receptor beta status in colorectal cancer.

2019

Involvement of sex hormones in colorectal cancer (CRC) development has been linked to oestrogen receptor β (ERβ). Expression of ERβ is found reduced in tumour tissue and inversely related to mortality. However, mechanisms are not well understood. Our study aimed to detect differentially methylated genes associated with ERβ expression, which could point to mechanisms by which ERβ could influence risk and prognosis of CRC. Epigenome-wide DNA methylation profiling was performed using Illumina HumanMethylation450k BeadChip arrays in two independent tumour sample sets of CRC patients recruited in 2003–2010 by the German DACHS study (discovery cohort n = 917, replication cohort n = 907). ERβ expr…

0301 basic medicineAdultMaleCancer ResearchColorectal cancerBiologyGenomeEpigenesis Genetic03 medical and health sciencesTumour tissue0302 clinical medicinemedicineBiomarkers TumorEstrogen Receptor betaHumansEpigeneticsOestrogen receptorBeta (finance)Promoter Regions GeneticMolecular BiologyAgedAged 80 and overDNA MethylationMiddle Agedmedicine.diseasePrognosisGene Expression Regulation NeoplasticSurvival Rate030104 developmental biology030220 oncology & carcinogenesisCase-Control StudiesDNA methylationCancer researchFemaleColorectal NeoplasmsHormoneFollow-Up StudiesGenome-Wide Association StudyResearch PaperEpigenetics
researchProduct

Pooled analysis of prospective European studies assessing the impact of using the 21-gene Recurrence Score assay on clinical decision making in women…

2016

PURPOSE: The 21-gene Recurrence Score assay (Oncotype DX) provides prognostic/predictive information in oestrogen receptor positive (ER+) early breast cancer, but access/reimbursement has been limited in most European countries in the absence of prospective outcome data. Recently, two large prospective studies and a real-life 5-year outcome study have been reported. We performed a pooled analysis of prospective European impact studies to generate robust data on impact of use in different clinical subgroups. METHODS: The analysis included four studies (French, German, Spanish, and British) in ER+ human epidermal growth factor receptor 2-negative breast cancer patients (n = 527). Node-positiv…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyReceptor ErbB-2medicine.medical_treatmentClinical Decision-MakingBreast NeoplasmsMama -- Càncer -- TractamentRisk AssessmentSeverity of Illness Index03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancerInternal medicineQuimioteràpiaHumansMedicineProspective StudiesOestrogen receptorPrecision MedicineStage (cooking)Prospective cohort studyReimbursementAgedAged 80 and overGynecologyChemotherapyIndividualised medicinemedicine.diagnostic_testbusiness.industryGene Expression ProfilingMiddle Agedmedicine.diseaseTumor BurdenAdjuvant chemotherapyEurope030104 developmental biologyReceptors EstrogenOncology030220 oncology & carcinogenesisHormonal therapyFemaleNeoplasm Recurrence LocalbusinessOncotype DXClinical decision makingEuropean Journal of Cancer
researchProduct

Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in pati…

2015

Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free su…

OncologyAdultAdjuvant taxanesCancer Researchmedicine.medical_specialtyAnthracyclinemedicine.medical_treatmenteducationBreast NeoplasmsDocetaxelDisease-Free SurvivalPooled analysisBreast cancerBreast cancerPredictive Value of TestsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIn patientAnthracyclinesOestrogen receptorProspective StudiesAgedER positivebusiness.industryMiddle Agedmedicine.diseaseImmunohistochemistryPooled analysisKi-67 AntigenOncologyDocetaxelBreast international groupChemotherapy AdjuvantFemaleTaxoidsbusinessAdjuvantKi67medicine.drug
researchProduct

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth f…

2014

Sir,We have read with great interest the article in press ofAurilio et al., A meta-analysis of oestrogen receptor, pro-gesterone receptor and human epidermal growth factorreceptor 2 discordance between primary breast cancerand metastases (http://dx.doi.org/10.1016/j.ejca.2003.10.004), which will appear in Eur J Cancer. In the paper,the Authors have performed a meta-analysis of the stud-ies published in the literature concerning the discor-dance rate in oestrogen receptor (ER), progesteronereceptor (PgR) and HER2 status between primarytumour and corresponding relapse. It is well known thata considerable controversy concerns the issue of hor-mone receptors (HRs) expression as well as HER2 sta…

OncologyCancer Researchmedicine.medical_specialtyPathologyLetter to the editorBreast NeoplasmsSettore MED/08 - Anatomia PatologicaErbB-2breast cancer metastases oestrogen receptor human epidermal growth factor receptor 2Internal medicineProgesterone receptorReceptorsmedicineHumansOestrogen receptorskin and connective tissue diseasesReceptorProgesteronebusiness.industryCancermedicine.diseaseEstrogenRegimenOncologyLOCALLY RECURRENT HORMONE-RECEPTOR HER2 STATUS IMPACTMeta-analysisBreast Neoplasms; Female; Humans; Receptor ErbB-2; Receptors Estrogen; Receptors ProgesteroneImmunohistochemistryFemalebusinessReceptor
researchProduct

Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer?

1989

In 101 breast cancer patients, measurement of oestrogen receptor status in multiple biopsies across a tumour reveals a highly significant difference in the proportion of patients remaining either disease-free (P less than 0.04) or alive (P less than 0.005), when those with uniformly receptor positive (++) primary tumours are matched with clinically comparable patients whose tumours were homogeneously receptor negative (--). Mean follow-up time was 85 months. The prognostic value of this discriminant is particularly striking in the 53 patients with involved nodes at presentation. Of these, 13 were (++) and seven remain alive of whom six are disease-free, whereas 24 of the 29 (--) patients ar…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classMammary glandBreast NeoplasmsBiologyBreast cancerInternal medicineClinical informationmedicineHumansOestrogen receptorReceptorSignificant differencemedicine.diseasePrognosisMenopauseEndocrinologymedicine.anatomical_structureOncologyReceptors EstrogenEstrogenFemaleMenopauseResearch ArticleBritish journal of cancer
researchProduct

High expression of progesterone receptor may be an adverse prognostic factor in oestrogen receptor-negative/progesterone receptor-positive breast can…

2021

Oestrogen receptor (ER)-negative (–) progesterone receptor (PgR)-positive (+) is the least common combination of steroid receptor expression observed in breast cancer. There are many controversies regarding the actual existence of ER–/PgR+ phenotype. In the current study, we aimed to perform comprehensive immunohistochemical re-evaluation of ER–/PgR+ breast cancers from multiple institutions. A total of 135 cases of ER–/PgR+ breast cancer were collected from 11 institutions from the period 2006–2020 and subsequently stained with three clinically validated anti-ER antibody clones: SP1 (Roche), 1D5 (Dako), and EP1 (Dako), and two anti-PgR antibody clones: 636 (Dako), and 1E2 (Roche). Clinicop…

breast cancerReceptors EstrogenOestrogen receptorReceptor ErbB-2immunohistochemistryHumansBreast NeoplasmsFemaleprognosisReceptors Progesteroneprogesterone receptorPathology and Forensic MedicinePathology
researchProduct